Literature DB >> 30411403

Two-dimensional speckle tracking to image ventricular-arterial coupling in uremia.

Fu-Yong Ye1, Yin-Ting Liang1, Xiao-Chun Lin1.   

Abstract

OBJECTIVE: To study ventricular-arterial coupling(VAC) in uremic patients by application of two-dimensional speckle tracing imaging (2DSTI).
METHODS: One hundred uremic patients were divided into two groups based on left ventricular ejection fraction (LVEF): group 1 with LVEF ≥ 5%, and group 2 with LVEF < 55%. Forty healthy subjects were recruited as a control group. Conventional echocardiography was performed; VAC components and myocardial performance index were calculated. Longitudinal strain (LS) of 17 segments was measured using 2DSTI. Mean base (LSBA ), papillary muscle (LSPM ), and apex values (LSAP ) were calculated.
RESULTS: Compared to subjects in the control group and group 1, subjects in group 2 exhibited decreased LV end-diastolic volume (EDV), end-systolic volume (ESV), LV mass index (LVMI), and VAC (P < 0.05). EF, fractional shortening (FS), end-systolic elastance (Ees) were significantly higher in group 2 (P < 0.05). SLBA , SLPM , and SLAP differed significantly among the groups (all P < 0.05). SLBA , SLPM , and SLAP correlated positively with Ees, EF, and FS (all P < 0.05) but negatively with arterial elastance (Ea), VAC, systemic vascular resistance index (SVRI), and rate-pressure product (RPP) (all P < 0.05). Multiple regression analysis revealed that relative wall thickness (RWT), LVMI, LSAP , and stroke works (SW) were independent predictors of VAC (b' = -0.443, 0.537, -0.470, and -0.491, all P < 0.05).
CONCLUSIONS: In patients with uremia, LV myocardial LS gradually decreased as LV systolic dysfunction decreased. VAC correlated negatively with left ventricular LS, and LSAP was an independent predictor for VAC.
© 2018 The Authors. Echocardiography Published by Wiley Periodicals, Inc.

Entities:  

Keywords:  arterial elastance; end-systolic elastance; left ventricular function; speckle tracking imaging; uremia; ventricular-arterial coupling

Mesh:

Year:  2018        PMID: 30411403      PMCID: PMC6587544          DOI: 10.1111/echo.14183

Source DB:  PubMed          Journal:  Echocardiography        ISSN: 0742-2822            Impact factor:   1.724


INTRODUCTION

In recent years, a large body of evidence has identified cardiac dysfunction as a serious complication and the major cause of death in patients suffering from chronic uremia.1 The pathophysiologic and clinical implications of cardiac function should be considered together with vascular effects because ventricular‐arterial coupling (VAC), or the interaction between the left ventricle and the systemic artery, is an important determinant of cardiovascular performance.2, 3, 4 Two‐dimensional speckle tracking imaging (2DSTI) has been introduced as a feasible and reproducible technique with which to analyze regional and global left ventricular (LV) strain. This modality may be used to objectively assess myocardial deformation and quantitatively analyze regional wall motion abnormalities. 2DSTI is also preferable for evaluation of apical segment movement because the approach used avoids the angle dependence of Doppler technology.5, 6 The aim of this paper was to assess the utility of 2DSTI for evaluation of cardiovascular stiffness and VAC in patients with uremia.

MATERIALS AND METHODS

Study population

This study enrolled 100 patients (52 male, 48 female; mean age ± SD, 48.6 ± 12.8 years; range, 21–63 years) with uremia seen at the Urology Department of our hospital during the period from January 2015 to December 2017. Subjects were divided into 2 groups: group 1 included subjects with normal LV systolic function; group 2 included patients with LV systolic dysfunction. Systolic dysfunction was defined as LV ejection fraction (LVEF) <55%. Patients were excluded if they had valvular disease, coronary heart disease, hypertrophic cardiomyopathy, congenital heart disease, or peripheral arterial disease. All uremic patients were on hemodialysis for 4 hours a day, 3 times a week. Patients without standardized treatment were excluded. Each patient underwent assessment by 2DSTI before hemodialysis. Forty healthy volunteers (20 male, 20 female; mean age, 44.80 ± 10.76 years; range, 22–65 years) who had no history of renal or cardiovascular disease were included as controls. All subjects included as controls had normal physical examination, echocardiographic, and electrocardiographic results. The study was approved by the Ethics Committee at Gaozhou People's Hospital, and each patient who participated in the study provided written informed consent.

Echocardiography

Two‐dimensional echocardiography was performed with a commercial ultrasound machine (iE33; Philips Healthcare, Andover, MA) equipped with an S5‐1 transducer (1–5 MHz). Conventional echocardiography was performed with the patient in the left lateral decubitus position. LV end‐diastolic diameter (EDD), LV end‐systolic diameter (ESD), LV posterior wall thickness (PWT), and interventricular septum thickness (IVST) were measured according to the criteria provided by the American Society of Echocardiography (Raleigh, NC). These parameters were used to calculate LV mass index (LVMI)7 and relative wall thickness (RWT).8 LV end‐diastolic volume (EDV) and end‐systolic volume (ESV), stroke volume (SV), and EF were measured with the apical biplane method. Cardiac output (CO) was obtained as SV × heart rate (HR), and cardiac index (CI) was derived from the ratio of CO to body surface area (BSA). All parameters above were measured in triplicate and averaged.

Ventricular‐arterial coupling

Arterial elastance (Ea) was estimated as end‐systolic pressure (ESP)/stroke volume (SV), with ESP estimated as systolic pressure × 0.9. LV end‐systolic elastance (Ees) was calculated as follows:where V 0 is LV volume when LV pressure = 0. Accordingly, VAC was calculated as Ea/Ees.9 Stroke works (SW) was obtained as ESP × SV;10 rate‐pressure product (RPP) was obtained as HR × SBP;11 systemic vascular resistance index (SVRI) was obtained as mean arterial pressure (MAP) × 80/CI.12

2D speckle tracking analysis

Offline strain measurements were performed with Qlab 8.0 software. Apical four‐, two‐, and three‐chamber views were obtained with frame rates >60 frame/sec. The regional four‐chamber view of the left ventricular apex was analyzed first. Three points were selected for analysis. The software program automatically provided an outline of the endocardium to produce a region of interest (ROI). ROI width was adjusted manually to reflect myocardial thickness.13 The system automatically generated longitudinal strain values for 5 or 6 segments. The same method was used to analyze the data provided in apical two‐ and three‐chamber views. The left ventricle was divided in accordance with the American Society of Echocardiography's 17‐segment model. A bull's eye display of longitudinal peak strain was obtained for all segments of the left ventricle. Mean longitudinal strain (LS) of myocardial segments including the base (LSBA), papillary muscle (LSPM), and apex (LSAP) were calculated.14

Statistical analysis

Statistical analyses were performed using SPSS 20.0 software (SPSS Inc, Chicago, IL). All data are expressed as mean values ± SD. Analysis of variance for multiple comparisons was used to assess between‐group differences. Pearson's correlation coefficients were applied to evaluate correlations between variables of interest. Multiple linear regression analysis was performed to explore the determinants of VAC. P < 0.05 was considered statistically significant.

RESULTS

Clinical characteristics

Descriptive characteristics of the patient population are presented in Table 1. There were no significant differences among the 3 groups in terms of age or gender. However, systolic blood pressure (SBP), mean arterial pressure (MAP), and heart rate (HR) were higher in the 2 groups with uremia than in the control group. Body mass index (BMI) was lower in the 2 groups with uremia than in the control group (P < 0.05) (Table 1).
Table 1

Clinical parameters of the study population

ParameterControl (n = 40)Group 1 (n = 50)Group 2 (n = 50) F P
Age, y44.80 ± 10.7647.50 ± 11.5749.6 ± 14.011.6950.187
Male/female20/2026/2426/240.974
BMI, kg/m2 22.74 ± 2.6321.09 ± 3.35a 21.24 ± 2.48a 4.3530.015
SBP, mmHg127.70 ± 17.07149.32 ± 22.33a 152.72 ± 24.34a 16.7210.000
MAP, mmHg96.52 ± 13.70109.87 ± 16.20a 110.73 ± 18.61a 10.0450.000
HR, bpm79.35 ± 9.6383.92 ± 7.63a 84.04 ± 8.73a 4.1150.018

Values (except male/female) are presented as mean ± SD.

BMI = body mass index; SBP = systolic blood pressure; MAP = mean arterial pressure; HR = heart rate.

P < 0.05 vs control.

Clinical parameters of the study population Values (except male/female) are presented as mean ± SD. BMI = body mass index; SBP = systolic blood pressure; MAP = mean arterial pressure; HR = heart rate. P < 0.05 vs control.

Conventional echocardiographic parameters and LV longitudinal strain

RWT and LVMI were higher in group 1, compared with the control group (P < 0.05). LSBA, LSPM, and LSAP were lower in group 1 (P < 0.05), compared with the control group. LVEDV, LVESV, and LVMI were significantly higher in group 2, compared with the control group and group 1 (P < 0.05). EF, FS, LSBA, LSPM, and LSAP were significantly lower in group 2 than in the control group and group 1 (P < 0.05). RWT was slightly higher in group 2 than in the control group, but this trend was not statistically significant. There were no differences across groups in SV, CO, or CI (Table 2, Figures 1, 2, 3).
Table 2

Results of conventional echocardiography vs. speckle tracking imaging

ParameterControl (n = 40)Group 1 (n = 50)Group 2 (n = 50) F P
LVEDV, mL85.47 ± 15.5693.61 ± 27.32129.14 ± 33.08a, b 34.8640.000
LVESV, mL28.31 ± 6.8833.28 ± 10.3171.45 ± 26.50a, b 87.4570.000
SV, mL57.16 ± 10.9060.33 ± 18.6357.69 ± 15.220.5640.570
CO, L/min4.56 ± 1.025.11 ± 1.574.87 ± 1.441.7610.176
CI, L·min−1·m−2 2.68 ± 0.583.09 ± 0.872.93 ± 0.833.0470.051
EF,·%66.85 ± 4.7264.4 ± 4.6845.74 ± 9.90a, b 128.10.000
FS,·%36.92 ± 3.6335.13 ± 3.4523.23 ± 5.72a, b 133.3130.000
RWT0.43 ± 0.040.56 ± 0.12a 0.47 ± 0.09b 23.0440.000
LVMI,·g/m2 78.50 ± 11.27127.84 ± 32.63a 149.69 ± 33.86a, b 69.9440.000
LSBA,·%17.08 ± 1.5114.12 ± 2.63a 11.18 ± 2.30a, b 77.2790.000
LSPM,·%20.53 ± 1.7517.32 ± 2.71a 13.46 ± 2.39a, b 101.3060.000
LSAP,·%24.65 ± 1.0821.88 ± 2.97a 14.32 ± 2.85a, b 207.2840.000

Data are presented as mean ± SD.

LVEDV = left ventricular end‐diastolic volume; LVESV = left ventricular end‐systolic volume; SV = stroke volume; CO = cardiac output; CI = cardiac index; FS = fractional shortening; RWT = relative wall thickness; LVMI = left ventricular mass index; LSBA = longitudinal strain at the level of the base; LSPM = longitudinal strain at the level of papillary muscles; LSAP = longitudinal strain at the level of the apex.

P < 0.05 vs control group.

P < 0.05 vs group 1.

Figure 1

2D longitudinal peak strain, presented as a “bull's eye” display. Representative image of a control subject

Figure 2

2D longitudinal peak strain, presented in a “bull's eye” display. Representative image from a uremic patient with normal LV systolic function

Figure 3

2D longitudinal peak strain, presented as a “bull's eye” display. Representative image from a uremic patient with LV systolic dysfunction

Results of conventional echocardiography vs. speckle tracking imaging Data are presented as mean ± SD. LVEDV = left ventricular end‐diastolic volume; LVESV = left ventricular end‐systolic volume; SV = stroke volume; CO = cardiac output; CI = cardiac index; FS = fractional shortening; RWT = relative wall thickness; LVMI = left ventricular mass index; LSBA = longitudinal strain at the level of the base; LSPM = longitudinal strain at the level of papillary muscles; LSAP = longitudinal strain at the level of the apex. P < 0.05 vs control group. P < 0.05 vs group 1. 2D longitudinal peak strain, presented as a “bull's eye” display. Representative image of a control subject 2D longitudinal peak strain, presented in a “bull's eye” display. Representative image from a uremic patient with normal LV systolic function 2D longitudinal peak strain, presented as a “bull's eye” display. Representative image from a uremic patient with LV systolic dysfunction

VAC components and myocardial performance index

With respect to VAC, Ea was significantly higher in group 2, compared with the control group. Ea values in group 2 were not significantly different from those reported for group 1. Ees and VAC values for group 2 differed significantly from those observed for the control group and group 1. Ees and VAC values were similar in the control group and group 1. RPP and SW were significantly higher in the 2 disease groups, compared with the control group. SVRI did not differ significantly among the 3 groups (Table 3).
Table 3

VAC components and myocardial performance index

ParameterControl (n = 40)Group 1 (n = 50)Group 2 (n = 50) F P
Ea, mmHg/mL2.08 ± 0.452.43 ± 0.812.58 ± 0.95a 4.6770.011
Ees, mmHg/mL4.32 ± 1.274.45 ± 1.572.22 ± 0.99a, b 44.8890.000
VAC (Ea/Ees)0.50 ± 0.110.56 ± 0.111.32 ± 0.66a, b 61.6330.000
RPP·mmHg·bpm10234 ± 209512760 ± 2534a 12858 ± 2595a 15.920.000
SW·mmHg·mL6601 ± 16458104 ± 2678a 7914 ± 2342a 5.4310.005
SVRI·N·m2·cm−5 0.030 ± 0.0080.031 ± 0.0110.033 ± 0.0120.9230.400

Data are presented as mean ± SD.

Ea = arterial elastance; Ees = end‐systolic elastance; VAC = ventricular‐arterial coupling; RPP = rate‐pressure product; SW = stroke works; SVRI = systemic vascular resistance index.

P < 0.05 vs control group.

P < 0.05 vs group 1.

VAC components and myocardial performance index Data are presented as mean ± SD. Ea = arterial elastance; Ees = end‐systolic elastance; VAC = ventricular‐arterial coupling; RPP = rate‐pressure product; SW = stroke works; SVRI = systemic vascular resistance index. P < 0.05 vs control group. P < 0.05 vs group 1.

Correlation analysis

Pearson correlation analysis was conducted to investigate the relationship between LV longitudinal strain and conventional cardiovascular parameters. For the overall study population, LSBA, LSPM, and LSAP were positively correlated with Ees, EF, and FS (all P < 0.05) and negatively correlated with Ea, VAC, SVRI, and RPP (all P < 0.05). No significant correlation with SW and RWT was observed. Multiple linear regression analysis showed that RWT, LVMI, LSAP, and SW were independent predictors of VAC. Standard regression coefficient b′ was −0.443, 0.537, −0.470, and −0.491, respectively (all P < 0.05) (Tables 4 and 5).
Table 4

Correlation of LV strain with cardiovascular variables

ParametersLSBA LSPM LSAP
Ea−0.36a −0.323a −0.348a
Ees0.385a 0.452a 0.561a
VAC−0.623a −0.643a −0.76a
SVRI−0.226a −0.185a −0.234a
SW0.051−0.0790.023
RPP−0.397a −0.359a −0.285a
RWT−0.123−0.135−0.033
LVMI−0.495a −0.567a −0.545a
EF0.683a 0.707a 0.84a
FS0.69a 0.707a 0.843a

P < 0.05.

Table 5

Multiple linear regression analysis to determine VAC in uremic patients

VariableRegression coefficient (b)Standard error (Sb)Standard regression coefficient (b′) t‐value P‐value
Constant2.9890.19415.3850.000
RWT−2.3770.270−0.443−8.8120.000
LVMI0.0070.0010.5377.4540.000
LSAP−0.0510.006−0.470−8.1040.000
SW0.0000.000−0.491−8.1180.000
Correlation of LV strain with cardiovascular variables P < 0.05. Multiple linear regression analysis to determine VAC in uremic patients

DISCUSSION

The principal finding of this observational study was that in patients with uremia, mean longitudinal strain accurately reflects arterial stiffness, myocardial performance, and VAC. In patients with uremia, LV myocardial LS decreased gradually as LV systolic dysfunction decreased. VAC is normal in uremic patients with normal LV systolic function but abnormal in those with LV systolic dysfunction. VAC correlated negatively with left ventricular LS, and LSAP was an independent predictor of VAC. Cardiovascular‐related issues are an important cause of death among patients with uremia. Chronic renal disease is associated with a high incidence of changes in cardiovascular morphology and function. Chronic renal disease is caused by several factors15: Hypertension may result in an enlarged heart, a thickened ventricular wall, and increased myocardial oxygen consumption. Chronic renal disease may also accelerate the process of arterial stiffening. Secondly, chronic hypervolemia may negatively impact the ventricular myocardium. Chronic hypervolemia may result in increased ventricular preload, increased oxygen requirement, and a stepwise increase in cardiac insufficiency. Finally, chronic anemia may lead to myocardial ischemia and hypoxia in uremic patients. Electrolyte imbalances may damage the myocardium, resulting in cardiac failure. Previous studies of cardiovascular disease in uremic patients have shown that age is a risk factor for cardiovascular‐related death.16 There was no significant difference in age or gender among the three groups included in our study, demonstrating that the factors above did not affect the research results. With respect to components of the VAC, Ea is an integrated index of the net arterial load imposed on the LV. Numerous disease states are characterized by elevated Ea.10 Ees is a measure of myocardial contractility reflecting the ability of the LV to eject blood, in opposition to a given pressure. An increase in Ees is usually associated with enhanced myocardial contractility. In addition, chronic changes in Ees also reflect passive myocardial stiffening and chamber geometry.17 VAC, a crucial determinant of cardiovascular performance, is reliably estimated by the ratio of Ea to Ees. Whereas studies of normal healthy subjects have shown optimal coupling at VAC values close to unity, the ventricle achieves maximal efficiency when VAC approaches 0.5.18, 19 In uremic patients, vascular sclerosis increases myocardial oxygen; myocardial stiffness further enhances this effect. Table 3 shows that RPP, a sensitive index of myocardial oxygen consumption, increased remarkably in uremic patients, as did SW, an index of myocardial performance. As the disease progresses, cardiovascular reserve decreases, with accompanying effects on the ventricular‐vascular interaction.19, 20 Increasing cardiac insufficiency induces stepwise deterioration of VAC. In this study, increased Ea and decreased Ees were observed in subjects with LV systolic dysfunction (group 2). VAC (Ea/Ees ratio) was <1.0 in subjects with normal LV systolic function (group 1). VAC was similar in group 1 and in the control group. In group 2, VAC was >1.0. This value is significantly higher than that observed in the control group or group 1. 2DSTI technology is a noninvasive tool that has recently garnered increasing interest among clinicians. This modality provides a quantitative analysis of segmental contractility and an objective evaluation of myocardial function.21, 22, 23 In our study, mean SL in two groups with uremia (group 1 and group 2) in the short‐axis view (LSBA, LSPM, and LSAP) was significantly decreased, especially in patients with LV systolic dysfunction (group 2). Correlation analysis revealed a moderate negative correlation between VAC and LSBA, LSPM, and LSAP (in all participants). Ees was positively correlated with LSBA, LSPM, LSAP; Ea was negatively correlated with LSBA, LSPM, and LSAP. Previous studies have investigated the determinants of VAC in hypertension and diastolic dysfunction.24, 25 In contrast to previous reports that neither LSBA nor LSPM shows changes in response to hypertensive stimuli, LV contractility is affected mainly by LSAP rather than LSBA or LSPM, suggesting that LSAP may contribute to VAC only partially.24, 25 Our results are consistent with these findings: changes in LSAP are a major determinant of VAC, whereas changes in LSBA and LSPM may have only minor effects on VAC.

LIMITATIONS

This study had some limitations. Firstly, the duration of uremia should be an important parameter when analyzing the effects of uremia on cardiac function and VAC. However, this study failed to analyze the duration of illness in uremic patients, as some patients did not know how long they had been suffering from uremia. Secondly, during dialysis treatment, blood biochemical parameters associated with uremia changed dynamically. This study did not include laboratory analysis. It is expected that in future studies, changes in cardiac function and VAC during this dynamic process will be analyzed. Finally, future studies should investigate global LS in uremic patients.

CONCLUSION

In conclusion, LV myocardial LS decreased gradually as LV systolic dysfunction decreased in patients with uremia. VAC was normal in uremic patients with normal LV systolic function but abnormal in patients with LV systolic dysfunction. VAC correlated negatively with left ventricular LS, and LSAP was an independent predictor for VAC.
  26 in total

1.  The Value of Left Ventricular Relative Wall Thickness in Predicting Ventricular Arrhythmia and Related Death.

Authors:  Julius M Gardin
Journal:  J Am Coll Cardiol       Date:  2016-01-26       Impact factor: 24.094

2.  Myocardial Damage Detected by Two-Dimensional Speckle-Tracking Echocardiography in Patients with Extracardiac Sarcoidosis: Comparison with Magnetic Resonance Imaging.

Authors:  Makoto Orii; Kumiko Hirata; Takashi Tanimoto; Yasutsugu Shiono; Kunihiro Shimamura; Takashi Yamano; Yasushi Ino; Tomoyuki Yamaguchi; Takashi Kubo; Atsushi Tanaka; Toshio Imanishi; Takashi Akasaka
Journal:  J Am Soc Echocardiogr       Date:  2015-03-30       Impact factor: 5.251

Review 3.  Ventricular arterial stiffening: integrating the pathophysiology.

Authors:  David A Kass
Journal:  Hypertension       Date:  2005-05-23       Impact factor: 10.190

4.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology.

Authors:  Roberto M Lang; Michelle Bierig; Richard B Devereux; Frank A Flachskampf; Elyse Foster; Patricia A Pellikka; Michael H Picard; Mary J Roman; James Seward; Jack S Shanewise; Scott D Solomon; Kirk T Spencer; Martin St John Sutton; William J Stewart
Journal:  J Am Soc Echocardiogr       Date:  2005-12       Impact factor: 5.251

Review 5.  Two-dimensional strain imaging: a new echocardiographic advance with research and clinical applications.

Authors:  N J Artis; D L Oxborough; G Williams; C B Pepper; L B Tan
Journal:  Int J Cardiol       Date:  2007-05-02       Impact factor: 4.164

6.  Echocardiographic evaluation and comparison of the effects of isoflurane, sevoflurane and desflurane on left ventricular relaxation indices in patients with diastolic dysfunction.

Authors:  Subhendu Sarkar; Rahul GuhaBiswas; Emmanuel Rupert
Journal:  Ann Card Anaesth       Date:  2010 May-Aug

7.  Quantifying exertion level during exercise stress testing using percentage of age-predicted maximal heart rate, rate pressure product, and perceived exertion.

Authors:  Sherry Pinkstaff; Mary Ann Peberdy; Michael C Kontos; Sheryl Finucane; Ross Arena
Journal:  Mayo Clin Proc       Date:  2010-12       Impact factor: 7.616

8.  Left ventricular torsion by two-dimensional speckle tracking echocardiography in patients with diastolic dysfunction and normal ejection fraction.

Authors:  Sung-Ji Park; Chinami Miyazaki; Charles J Bruce; Steve Ommen; Fletcher A Miller; Jae K Oh
Journal:  J Am Soc Echocardiogr       Date:  2008-05-19       Impact factor: 5.251

9.  Left ventricular twist and ventricular-arterial coupling in hypertensive patients.

Authors:  Hong-Won Shin; Hyungseop Kim; Jeong-Eun Lee; In-Cheol Kim; Hyuck-Jun Yoon; Hyoung-Seob Park; Yun-Kyeong Cho; Chang-Wook Nam; Seung-Ho Hur; Yoon-Nyun Kim; Kwon-Bae Kim
Journal:  Echocardiography       Date:  2014-03-19       Impact factor: 1.724

10.  Two-dimensional speckle tracking to image ventricular-arterial coupling in uremia.

Authors:  Fu-Yong Ye; Yin-Ting Liang; Xiao-Chun Lin
Journal:  Echocardiography       Date:  2018-11-08       Impact factor: 1.724

View more
  1 in total

1.  Two-dimensional speckle tracking to image ventricular-arterial coupling in uremia.

Authors:  Fu-Yong Ye; Yin-Ting Liang; Xiao-Chun Lin
Journal:  Echocardiography       Date:  2018-11-08       Impact factor: 1.724

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.